Literature DB >> 25486447

Structure guided lead generation for M. tuberculosis thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1,6-naphthyridin-2-one as potent inhibitors.

Maruti Naik1, Anandkumar Raichurkar, Balachandra S Bandodkar, Begur V Varun, Shantika Bhat, Rajesh Kalkhambkar, Kannan Murugan, Rani Menon, Jyothi Bhat, Beena Paul, Harini Iyer, Syeed Hussein, Julie A Tucker, Martin Vogtherr, Kevin J Embrey, Helen McMiken, Swati Prasad, Adrian Gill, Bheemarao G Ugarkar, Janani Venkatraman, Jon Read, Manoranjan Panda.   

Abstract

M. tuberculosis thymidylate kinase (Mtb TMK) has been shown in vitro to be an essential enzyme in DNA synthesis. In order to identify novel leads for Mtb TMK, we performed a high throughput biochemical screen and an NMR based fragment screen through which we discovered two novel classes of inhibitors, 3-cyanopyridones and 1,6-naphthyridin-2-ones, respectively. We describe three cyanopyridone subseries that arose during our hit to lead campaign, along with cocrystal structures of representatives with Mtb TMK. Structure aided optimization of the cyanopyridones led to single digit nanomolar inhibitors of Mtb TMK. Fragment based lead generation, augmented by crystal structures and the SAR from the cyanopyridones, enabled us to drive the potency of our 1,6-naphthyridin-2-one fragment hit from 500 μM to 200 nM while simultaneously improving the ligand efficiency. Cyanopyridone derivatives containing sulfoxides and sulfones showed cellular activity against M. tuberculosis. To the best of our knowledge, these compounds are the first reports of non-thymidine-like inhibitors of Mtb TMK.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25486447     DOI: 10.1021/jm5012947

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Editorial: Medicinal Chemistry Research in India.

Authors:  Ram Vishwakarma
Journal:  ACS Med Chem Lett       Date:  2017-03-09       Impact factor: 4.345

2.  Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis.

Authors:  Divneet Kaur; Shalu Mathew; Chinchu G S Nair; Azitha Begum; Ashwin K Jainanarayan; Mukta Sharma; Samir K Brahmachari
Journal:  J Transl Med       Date:  2017-12-21       Impact factor: 5.531

3.  1-(1-Arylethylpiperidin-4-yl)thymine Analogs as Antimycobacterial TMPK Inhibitors.

Authors:  Yanlin Jian; Fabian Hulpia; Martijn D P Risseeuw; He Eun Forbes; Guy Caljon; Hélène Munier-Lehmann; Helena I M Boshoff; Serge Van Calenbergh
Journal:  Molecules       Date:  2020-06-17       Impact factor: 4.411

4.  The structural basis of unique substrate recognition by Plasmodium thymidylate kinase: Molecular dynamics simulation and inhibitory studies.

Authors:  Mahmoud Kandeel; Yukio Kitade; Abdulla Al-Taher; Mohammed Al-Nazawi
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

Review 5.  Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.

Authors:  Vaishali P Waman; Sundeep Chaitanya Vedithi; Sherine E Thomas; Bridget P Bannerman; Asma Munir; Marcin J Skwark; Sony Malhotra; Tom L Blundell
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

6.  Accelerating high-throughput virtual screening through molecular pool-based active learning.

Authors:  David E Graff; Eugene I Shakhnovich; Connor W Coley
Journal:  Chem Sci       Date:  2021-04-29       Impact factor: 9.825

7.  In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Mycobacterium tuberculosis.

Authors:  Katharigatta N Venugopala; Christophe Tratrat; Melendhran Pillay; Sandeep Chandrashekharappa; Omar Husham Ahmed Al-Attraqchi; Bandar E Aldhubiab; Mahesh Attimarad; Osama I Alwassil; Anroop B Nair; Nagaraja Sreeharsha; Rashmi Venugopala; Mohamed A Morsy; Michelyne Haroun; Hezekiel M Kumalo; Bharti Odhav; Koleka Mlisana
Journal:  Drug Des Devel Ther       Date:  2020-03-09       Impact factor: 4.162

8.  Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.

Authors:  Candice Soares de Melo; Vinayak Singh; Alissa Myrick; Sandile B Simelane; Dale Taylor; Christel Brunschwig; Nina Lawrence; Dirk Schnappinger; Curtis A Engelhart; Anuradha Kumar; Tanya Parish; Qin Su; Timothy G Myers; Helena I M Boshoff; Clifton E Barry; Frederick A Sirgel; Paul D van Helden; Kirsteen I Buchanan; Tracy Bayliss; Simon R Green; Peter C Ray; Paul G Wyatt; Gregory S Basarab; Charles J Eyermann; Kelly Chibale; Sandeep R Ghorpade
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.